684 related articles for article (PubMed ID: 11018095)
21. Serum levels of IGF-I, IGFBP-3 and colorectal cancer risk: results from the EPIC cohort, plus a meta-analysis of prospective studies.
Rinaldi S; Cleveland R; Norat T; Biessy C; Rohrmann S; Linseisen J; Boeing H; Pischon T; Panico S; Agnoli C; Palli D; Tumino R; Vineis P; Peeters PH; van Gils CH; Bueno-de-Mesquita BH; Vrieling A; Allen NE; Roddam A; Bingham S; Khaw KT; Manjer J; Borgquist S; Dumeaux V; Torhild Gram I; Lund E; Trichopoulou A; Makrygiannis G; Benetou V; Molina E; Donate Suárez I; Barricarte Gurrea A; Gonzalez CA; Tormo MJ; Altzibar JM; Olsen A; Tjonneland A; Grønbaek H; Overvad K; Clavel-Chapelon F; Boutron-Ruault MC; Morois S; Slimani N; Boffetta P; Jenab M; Riboli E; Kaaks R
Int J Cancer; 2010 Apr; 126(7):1702-15. PubMed ID: 19810099
[TBL] [Abstract][Full Text] [Related]
22. IGF-1, IGF-2 and IGFBP-3 in prediagnostic serum: association with colorectal cancer in a cohort of Chinese men in Shanghai.
Probst-Hensch NM; Yuan JM; Stanczyk FZ; Gao YT; Ross RK; Yu MC
Br J Cancer; 2001 Nov; 85(11):1695-9. PubMed ID: 11742490
[TBL] [Abstract][Full Text] [Related]
23. Insulin-like Growth Factor-1, IGF-binding Protein-3, C-peptide and Colorectal Cancer: a Case-control Study.
Pankaj J; Kumari JR; Kim W; Lee SA
Asian Pac J Cancer Prev; 2015; 16(9):3735-40. PubMed ID: 25987030
[TBL] [Abstract][Full Text] [Related]
24. IGF-Binding Proteins, Adiponectin, and Survival in Metastatic Colorectal Cancer: Results From CALGB (Alliance)/SWOG 80405.
Guercio BJ; Zhang S; Ou FS; Venook AP; Niedzwiecki D; Lenz HJ; Innocenti F; Pollak MN; Nixon AB; Mullen BC; O'Neil BH; Shaw JE; Polite BN; Benson AB; Atkins JN; Goldberg RM; Brown JC; O'Reilly EM; Mayer RJ; Blanke CD; Fuchs CS; Meyerhardt JA
JNCI Cancer Spectr; 2021 Feb; 5(1):. PubMed ID: 33426464
[TBL] [Abstract][Full Text] [Related]
25. Insulin-like growth factors, insulin-like growth factor-binding proteins, and endometrial cancer in postmenopausal women: results from a U.S. case-control study.
Lacey JV; Potischman N; Madigan MP; Berman ML; Mortel R; Twiggs LB; Barrett RJ; Wilbanks GD; Lurain JR; Fillmore CM; Sherman ME; Brinton LA
Cancer Epidemiol Biomarkers Prev; 2004 Apr; 13(4):607-12. PubMed ID: 15066926
[TBL] [Abstract][Full Text] [Related]
26. Plasma insulin-like growth factor 1, insulin-like growth factor binding protein 3, and risk of colorectal cancer: a prospective study in northern Sweden.
Palmqvist R; Hallmans G; Rinaldi S; Biessy C; Stenling R; Riboli E; Kaaks R
Gut; 2002 May; 50(5):642-6. PubMed ID: 11950809
[TBL] [Abstract][Full Text] [Related]
27. Prostate cancer risk in relation to insulin-like growth factor (IGF)-I and IGF-binding protein-3: A nested case-control study in large scale cohort study in Japan.
Mikami K; Ozasa K; Nakao M; Miki T; Hayashi K; Watanabe Y; Mori M; Sakauchi F; Washio M; Kubo T; Suzuki K; Wakai K; Nakachi K; Tajima K; Ito Y; Inaba Y; Tamakoshi A;
Asian Pac J Cancer Prev; 2009 Dec; 10 Suppl():57-61. PubMed ID: 20553083
[TBL] [Abstract][Full Text] [Related]
28. Dietary determinants of circulating insulin-like growth factor (IGF)-I and IGF binding proteins 1, -2 and -3 in women in the Netherlands.
Vrieling A; Voskuil DW; Bueno de Mesquita HB; Kaaks R; van Noord PA; Keinan-Boker L; van Gils CH; Peeters PH
Cancer Causes Control; 2004 Oct; 15(8):787-96. PubMed ID: 15456992
[TBL] [Abstract][Full Text] [Related]
29. Insulin-like growth factor II and colorectal cancer risk in women.
Hunt KJ; Toniolo P; Akhmedkhanov A; Lukanova A; Dechaud H; Rinaldi S; Zeleniuch-Jacquotte A; Shore RE; Riboli E; Kaaks R
Cancer Epidemiol Biomarkers Prev; 2002 Sep; 11(9):901-5. PubMed ID: 12223436
[TBL] [Abstract][Full Text] [Related]
30. Effects of hormone replacement therapy on insulin-like growth factor (IGF)-I, IGF-II and IGF binding protein (IGFBP)-1 to IGFBP-4: implications for cardiovascular risk.
Heald A; Kaushal K; Anderson S; Redpath M; Durrington PN; Selby PL; Gibson MJ
Gynecol Endocrinol; 2005 Mar; 20(3):176-82. PubMed ID: 16019358
[TBL] [Abstract][Full Text] [Related]
31. Serum concentrations of IGF-I, IGFBP-3 and c-peptide and risk of hyperplasia and cancer of the breast in postmenopausal women.
Schairer C; Hill D; Sturgeon SR; Fears T; Pollak M; Mies C; Ziegler RG; Hoover RN; Sherman ME
Int J Cancer; 2004 Feb; 108(5):773-9. PubMed ID: 14696106
[TBL] [Abstract][Full Text] [Related]
32. Serum levels of C-peptide, IGFBP-1 and IGFBP-2 and endometrial cancer risk; results from the European prospective investigation into cancer and nutrition.
Cust AE; Allen NE; Rinaldi S; Dossus L; Friedenreich C; Olsen A; Tjønneland A; Overvad K; Clavel-Chapelon F; Boutron-Ruault MC; Linseisen J; Chang-Claude J; Boeing H; Schulz M; Benetou V; Trichopoulou A; Trichopoulos D; Palli D; Berrino F; Tumino R; Mattiello A; Vineis P; Quirós JR; Agudo A; Sánchez MJ; Larrañaga N; Navarro C; Ardanaz E; Bueno-de-Mesquita HB; Peeters PH; van Gils CH; Bingham S; Khaw KT; Key T; Slimani N; Riboli E; Kaaks R
Int J Cancer; 2007 Jun; 120(12):2656-64. PubMed ID: 17285578
[TBL] [Abstract][Full Text] [Related]
33. Effects of GH and/or sex steroids on circulating IGF-I and IGFBPs in healthy, aged women and men.
Münzer T; Rosen CJ; Harman SM; Pabst KM; St Clair C; Sorkin JD; Blackman MR
Am J Physiol Endocrinol Metab; 2006 May; 290(5):E1006-13. PubMed ID: 16390864
[TBL] [Abstract][Full Text] [Related]
34. Growth retardation in constitutionally short children is related both to low serum levels of insulin-like growth factor-I and to its reduced bioavailability.
Lindgren BF; Segovia B; Lassarre C; Binoux M; Gourmelen M
Growth Regul; 1996 Sep; 6(3):158-64. PubMed ID: 8894649
[TBL] [Abstract][Full Text] [Related]
35. Serum insulin-like growth factor-I and breast cancer.
Toniolo P; Bruning PF; Akhmedkhanov A; Bonfrer JM; Koenig KL; Lukanova A; Shore RE; Zeleniuch-Jacquotte A
Int J Cancer; 2000 Dec; 88(5):828-32. PubMed ID: 11072255
[TBL] [Abstract][Full Text] [Related]
36. Evaluation of the components of insulin-like growth factor (IGF)-IGF binding protein (IGFBP) system in adolescents with type 1 diabetes and persistent microalbuminuria: relationship with increased urinary excretion of IGFBP-3 18 kD N-terminal fragment.
Spagnoli A; Chiarelli F; Vorwerk P; Boscherini B; Rosenfeld RG
Clin Endocrinol (Oxf); 1999 Nov; 51(5):587-96. PubMed ID: 10594519
[TBL] [Abstract][Full Text] [Related]
37. Decreased bioavailability of insulin-like growth factor-I, a cause of catabolism in hemodialysis patients?
Lindgren BF; Odar-Cederlöf I; Ericsson F; Brismar K
Growth Regul; 1996 Sep; 6(3):137-43. PubMed ID: 8894646
[TBL] [Abstract][Full Text] [Related]
38. Growth promoting peptides in diabetic and non-diabetic pregnancy: interactions with trophoblastic receptors and serum carrier proteins.
Culler FL; Tung RF; Jansons RA; Mosier HD
J Pediatr Endocrinol Metab; 1996; 9(1):21-9. PubMed ID: 8887130
[TBL] [Abstract][Full Text] [Related]
39. Plasma insulin, IGF-binding proteins-1 and -2 and risk of colorectal cancer: a prospective study in northern Sweden.
Palmqvist R; Stattin P; Rinaldi S; Biessy C; Stenling R; Riboli E; Hallmans G; Kaaks R
Int J Cancer; 2003 Oct; 107(1):89-93. PubMed ID: 12925961
[TBL] [Abstract][Full Text] [Related]
40. Growth hormone-binding protein is directly and IGFBP-3 is inversely associated with risk of female breast cancer.
Pazaitou-Panayiotou K; Kelesidis T; Kelesidis I; Kaprara A; Blakeman J; Vainas I; Mpousoulegas A; Williams CJ; Mantzoros C
Eur J Endocrinol; 2007 Feb; 156(2):187-94. PubMed ID: 17287408
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
